Related Experiment Video
Updated: Sep 14, 2025
CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors
Published on: September 14, 2019
Advances in MicroRNAs in Pathophysiology of Duchenne Muscular Dystrophy
Jose Emilio Galeazzi Aguilar1,2, Tomas Almeida-Becerril1, Maricela Rodríguez-Cruz1
1Laboratorio de Nutrición Molecular, Unidad de Investigación Médica en Nutrición, Hospital de Pediatría, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, México.
Abstract:
Duchenne muscular dystrophy (DMD) is a severe, progressive muscle disorder caused by pathogenic variants in the DMD gene, which encodes dystrophin, a protein essential for maintaining muscle integrity. Reduced or absent dystrophin expression results in sarcolemmal instability, chronic inflammation, oxidative stress, impaired muscle regeneration, and fibrosis. MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression post-transcriptionally and significantly influence multiple pathological processes in DMD. Specific miRNAs, including miR-146a, miR-155, miR-378, and miR-711, modulate inflammation primarily through the NF-κB signaling pathway. Others, such as miR-21, miR-31, miR-128, miR-144, and miR-379, regulate oxidative stress responses via the NRF2 antioxidant pathway. Muscle-specific miRNAs (myomiRs), notably miR-1, miR-133a/b, miR-206, miR-486, and miR-499, are critical for muscle regeneration, and their dysregulation impairs satellite cell function and muscle repair. Additionally, miRNAs such as miR-21, miR-29a/c, and miR-199a-5p play significant roles in fibrosis development. The dysregulation of these miRNAs contributes to the complex pathophysiology of DMD, underscoring their potential as biomarkers for disease progression and therapeutic response. Understanding the specific roles of these miRNAs provides valuable insights into the molecular mechanisms underlying DMD and may facilitate the identification of novel therapeutic targets.
Insights
MicroRNAs (miRNAs) are key regulators in Duchenne muscular dystrophy (DMD), impacting inflammation, oxidative stress, regeneration, and fibrosis. Understanding these small non-coding RNAs offers insights into DMD pathology and potential therapeutic targets.
Area of Science:
- Biochemistry
- Molecular Biology
- Genetics
Background:
- Duchenne muscular dystrophy (DMD) is a severe genetic disorder caused by mutations in the DMD gene, leading to dystrophin deficiency.
- Dystrophin absence causes muscle instability, inflammation, oxidative stress, impaired regeneration, and fibrosis, driving disease progression.
- MicroRNAs (miRNAs) are small non-coding RNAs that post-transcriptionally regulate gene expression and are implicated in DMD pathophysiology.
Purpose of the Study:
- To investigate the multifaceted roles of specific miRNAs in the molecular mechanisms underlying Duchenne muscular dystrophy.
- To highlight the involvement of miRNAs in key pathological processes of DMD, including inflammation, oxidative stress, muscle regeneration, and fibrosis.
- To explore the potential of miRNAs as biomarkers for DMD progression and therapeutic response.
Main Methods:
- Literature review and analysis of existing research on miRNA dysregulation in Duchenne muscular dystrophy.
- Identification of specific miRNAs and their target pathways involved in DMD pathology.
- Synthesis of information regarding the functional impact of miRNAs on inflammation (NF-κB), oxidative stress (NRF2), muscle regeneration (myomiRs), and fibrosis.
Main Results:
- Specific miRNAs (e.g., miR-146a, miR-155) modulate inflammation via the NF-κB pathway.
- Other miRNAs (e.g., miR-21, miR-128) regulate oxidative stress through the NRF2 pathway.
- Muscle-specific miRNAs (myomiRs) are crucial for muscle regeneration, and their dysregulation impairs satellite cell function; miRNAs also contribute to fibrosis.
Conclusions:
- Dysregulated miRNAs are integral to the complex pathophysiology of Duchenne muscular dystrophy.
- These miRNAs represent promising biomarkers for monitoring disease progression and evaluating therapeutic interventions.
- Targeting specific miRNAs may offer novel therapeutic strategies for Duchenne muscular dystrophy.
More Related Videos
06:51Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
Published on: August 10, 2018
05:16Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
Published on: May 7, 2020
Related Concept Videos
01:21Satellite Stem Cells and Muscular Dystrophy
01:22MicroRNAs
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
01:13Formation of Muscle Fibers from Myoblasts
Muscle progenitor cells (MPCs) are formed from the myotomes. MPCs express genes that encode the transcription factors Pax3 and Pax7. Along with Pax 3/7, other transcription...